International Journal of Advanced and Integrated Medical Sciences

Register      Login

VOLUME 2 , ISSUE 4 ( 2017 ) > List of Articles


Sensorineural Hearing Loss in Adults: Etiological Study

Saurabh Varshney, Sampan S Bist, Shishir Gupta

Keywords : Etiology, Hearing loss, Sensorineural

Citation Information : Varshney S, Bist SS, Gupta S. Sensorineural Hearing Loss in Adults: Etiological Study. Int J Adv Integ Med Sci 2017; 2 (4):178-182.

DOI: 10.5005/jp-journals-10050-10101

License: CC BY-SA 4.0

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2017; The Author(s).


Introduction Sensorineural hearing loss (SNHL) is an extremely common disorder, with a spectrum of effect ranging from an almost undetectable degree of disability to a profound alteration in the ability to function in society. The purpose of this study was to identify patients with SNHL and to establish an etiological diagnosis. Study design It was a prospective study. Materials and methods Patients with SNHL attending the Department of ENT at a tertiary referral center in the state of Uttarakhand were evaluated; 135 patients with audiologically proven SNHL were included in this study and were evaluated to make an etiological diagnosis. Results Sensorineural hearing loss was found predominantly in males with a mean age of 45.5 years. The maximum patients were in the age group of 26 to 45 years (54 patients; 40%). The maximum incidence of SNHL was found in office workers (49 patients; 36.3%). A total of 119 (88%) patients reported to have a progressive hearing loss while only 16 (12%) patients had a sudden onset of hearing loss; 69 (51%) cases had unilateral and 66 (49%) cases had bilateral hearing loss. The patients with moderate hearing loss (41–55 dB) were 33 (24.4%), while profound deafness (more than 90 dB) was seen in 31 (23%). A maximum of 66 (49%) patients were diagnosed as having a cochlear disease and retrocochlear disease was seen in 38 patients (28%) The most common etiology of SNHL was idiopathic while the second most common was presbycusis followed by noise-induced deafness and Meniere's disease. Conclusion It was found that the majority of the patients with SNHL were males belonging to younger age group and therefore, had a greater significance of early identification and rehabilitation. The main etiological diagnosis in our study was idiopathic followed by presbycusis. How to cite this article Bist SS, Varshney S, Gupta S, Bhagat S. Sensorineural Hearing Loss in Adults: Etiological Study. Int J Adv Integ Med Sci 2017;2(4):178-182.

PDF Share
  1. Angeli SI, Yan D, Telischi F, Balkany TJ, Ouyang XM, Du LL, Eshraghi A, Goodwin L, Liu XZ. Etiologic diagnosis of sensorineural hearing loss in adults. Otolaryngol Head Neck Surg 2005 Jun;132(6):890-895.
  2. Wellman MB, Sommer DD, McKenna J. Sensorineural hearing loss in postmeningitic children. Otol Neurotol 2003 Nov;24(6):907-912.
  3. Mamak A, Suleyman Y, Cansiz H, Inci E, Gulcu E, Derekoylu L. A study of prognostic factors in sudden hearing loss. Ear Nose Throat J 2005 Oct;84(10):641-644.
  4. Shargorodsky J, Curhan SG, Eavey R, Curhan GC. A prospective study of cardiovascular risk factors and incident hearing loss in men. Laryngoscope 2010 Sep;120(9):1887-1891.
  5. Wood VH, Bird PA, Giles EC, Baber WJ. Unsuccessful cochlear implantation in two patients with superficial siderosis of the central nervous system. Otol Neurol 2008 Aug;29(5):622-625.
  6. Wang LF, Kuo WR, Ho KY, Lee KW, Lin CS. A long-term study on hearing status in patients with nasopharyngeal carcinoma after radiotherapy. Otol Neurotol 2004 Mar;25(2):168-173.
  7. Shah RK, Blevins NH, Karmody CS. Mid frequency sensorineural hearing loss. J Laryngol Otol 2005 Jul;119(7):529-533.
  8. Segal N, Shkolink M, Kochba A, Segal A, Kraus M. Asymmetric hearing loss in a random population of patients with mild to moderate sensorineural hearing loss. Ann Otol Rhinol Laryngol 2007 Jan;116(1):7-10.
  9. Cruickshanks KJ, Tweed TS, Wiley TL, Klein BE, Klein R, Chappell R, Nondahl DM, Dalton DS. The 5 year incidence and progression of hearing loss: the epidemiology of hearing loss study. Arch Otolaryngol Head Neck Surg 2003 Oct;129(10):1041-1046.
  10. Yimtae K, Srirompotong S, Kraitrakul S. Idiopathic sudden sensorineural hearing loss. J Med Assoc Thai 2001 Jan;84(1):113-119.
  11. Fetterman BL, Williiam M, Saunders JE. Sudden bilateral hearing loss. Laryngoscope 1996 Nov;106(11):1347-1350.
  12. Sonkhya N, Kaur K. Evaluation of tone decay and short increment sensitivity index test in 50 cases of SNHL. Indian J Otol 2002;8(2):43-46.
  13. Surján L, Dévald J, Pálfalvi L. Epidemiology of hearing loss. Audiology 1973 Sep-Dec;12(5):396-410.
  14. Makishima K. Clinicopathological studies in presbycusis. Otol Fukuoka 1967;13(3):333.
  15. Hinchcliffe R. The Threshold of hearing as a function of age. Acoustica 1959;9:303.
  16. Fligor BJ, Cox LC. Output levels of commercially available portable compact disc players and the potential risk to hearing. Ear Hear 2004 Dec;25(6):513-527.
  17. Cox HJ, Ford GR. Hearing loss associated with weapons noise exposure: when to investigate an asymmetrical loss. J Laryngol Otol 1995 Apr;109(4):291-295.
  18. Taylor GD, Williams E. Acoustic trauma in sports hunter. Laryngoscope 1966 May;76(5):869-879.
  19. Nondahl DM, Cruickshanks KJ, Wiley TL, Klein R, Klein BE, Tweed TS. Recreational firearm use and hearing loss. Arch Fam Med 2000 Apr;9(4):352-357.
  20. Shakeel RS. Fortnightly review: diagnosis and treatment of Meniere's disease. BMJ 1998 Jan 31;316(7128):368-372.
  21. Paparella MM, Mancini F. Vestibular Meniere's disease. Otolaryngol Head Neck Surg 1985 Apr;93(2):148-151.
  22. Meyerhoff WL, Paparella MM, Gudbrandson FK. Clinical evaluation of Meniere's disease. Laryngoscope 1981 Oct;91(10):1663-1668.
  23. Vaughan N, James K, McDermott D, Griest S, Fausti S. A 5-year prospective study of diabetes and hearing loss in a veteran population. Otol Neurotol 2006 Jan;27(1):37-43.
  24. Tosi A, Misciali C, Piraccini B, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994 Apr;10(4):310-317.
  25. Bronner AK, Hood AF. Cutaneous complication of chemotherapeutic agents. J Am Acad Dermatol 1983 Nov;9(5):645-663.
  26. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 1986 Jan;70(1):187-209.
  27. Boyle DM, Engelking C. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995 Jan-Feb;22(1):57-67.
  28. Malkinson, FD. Radiobiology of the skin. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 5th edn. New York: McGraw-Hill; 1999. pp. 1514-1523.
  29. Goldschmidt H, Breneman JC, Bareneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994 Feb;30(2 Pt 1):157-182.
  30. Narkiewicz K, van de Borne P, Montano N, Hering D, Kara T, Somers VK. Sympathetic neural outflow and chemoreflex sensitivity are related to spontaneous breathing rate in normal men. Hypertension 2006;47(1):51-55.
  31. Agte VV, Chiplonkar SA. Sudarshan kriya yoga for improving antioxidant status and reducing anxiety in adults. Altern Complement Ther 2008;14(2):96-100.
  32. Jacobs GD. Clinical applications of the relaxation response and mind-body interventions. J Altern Complement Med 2001;7(Suppl 1):S93-S101.
  33. Singh N, Telles S. Heart rate variability and state anxiety in hypertensives and diabetes after one week of yoga. J Indian Psychol 2009;27(1-2):13-20.
  34. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. J Hum Hypertens 2004 Mar;18(3):139-185.
  35. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011 Jul-Aug;27(4):415-433.e1-2.
  36. Wahlgren NG, MacMahon DG, De Keyser JF, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994 May;4(3):204-10.
  37. Kaste M, Fogelholm R, Erilä T, Palomäki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994 Jul;25(7):1348-1353.
  38. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003 Jul;34(7):1699-1703.
  39. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011 Feb;377(9767):741-750.
  40. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009 Jan;8(1):48-56.
  41. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010 Aug;9(8):767-775.
  42. Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke 2013 Mar;44(3):870-947.
  43. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Stroke 2009 Jul;40(7):2442-2449.
  44. Karachalios GN, Charalabopoulos A, Papalimneou V, Kiortsis D, Dimicco P, Kostoula OK, Charalabopoulos K. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract 2005 May;59(5):562-570.
  45. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-1041.
  46. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005 Jun;36(6):1218-1226.
  47. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008 Sep;359(12):1225-1237.
  48. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2014 Jan:45(7):2160-2236.
  49. Robb AO, Mills NL, Din JN, Smith IB, Paterson F, Newby DE, Denison FC. Influence of the menstrual cycle, pregnancy, and preeclampsia on arterial stiffness. Hypertension 2009 Jun;53(6):952-958.
  50. Avni B, Frenkel G, Shahar L, Golik A, Sherman D, Dishy V. Aortic stiffness in normal and hypertensive pregnancy. Blood Press 2010 Feb;19(1):11-15.
  51. Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol 2012 Jul;40(1):28-34.
  52. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992 Feb;304(6824):405-412.
  53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar;359(9311):995-1003.
  54. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trials-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep;366(9489):895-906.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.